{"id":1678,"date":"2019-06-04T09:54:10","date_gmt":"2019-06-04T07:54:10","guid":{"rendered":"https:\/\/www.nanexa.com\/?p=1678"},"modified":"2019-06-04T09:54:10","modified_gmt":"2019-06-04T07:54:10","slug":"beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019","status":"publish","type":"post","link":"https:\/\/nanexa.com\/sv\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/","title":{"rendered":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019"},"content":{"rendered":"<p><strong>Pressmeddelande<\/strong><\/p>\n<p>Uppsala 2019-06-04<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019<\/strong><\/p>\n<p>En grupp aktie\u00e4gare i Nanexa AB, som tillsammans representerar minst 9,7 procent av samtliga aktier och r\u00f6ster, har meddelat bolaget att de p\u00e5 \u00e5rsst\u00e4mman den 11 juni 2019 avser att l\u00e4gga fram f\u00f6ljande f\u00f6rslag.<\/p>\n<p>Styrelsen f\u00f6resl\u00e5s best\u00e5 av sex ordinarie ledam\u00f6ter utan suppleanter. Till ledam\u00f6ter f\u00f6resl\u00e5s omval av Hans Arwidson (ordf\u00f6rande), Bengt Gustavsson och Magnus Westgren samt nyval av Urban Paulsson, Otto Skolling och Anders Johansson.<\/p>\n<p>Urban Paulsson \u00e4r jurist fr\u00e5n Lunds universitet med examen 1988. Han har arbetat mer \u00e4n 25 \u00e5r inom l\u00e4kemedelsindustrin med olika legala fr\u00e5gor och i olika roller bl.a. som General Counsel och Vice Pesident Corporate Development p\u00e5 Camurus AB och General Counsel p\u00e5 Vitrolife AB. Han har under de senaste \u00e5ret varit med och startat fyra biotech f\u00f6retag, bl.a. Coromant som avyttrades till Bristor-Myers Squibb. Tidigare har han arbetat som jurist och partner p\u00e5 advokatfirmorna Bird&amp;Bird och Nordia.<\/p>\n<p>Otto Skolling \u00e4r civilingenj\u00f6r fr\u00e5n KTH. Han har arbetat mer \u00e4n 25 \u00e5r inom l\u00e4kemedelsindustrin inom fr\u00e4mst aff\u00e4rsutveckling och finansiering men \u00e4ven produktutveckling. Otto har bl.a. arbetat p\u00e5 Pharmacia-UpJohn (Project director), Novozymes (Director Product Pipeline, Business Development &amp; Director M&amp;S Biopharmaceutical ingredients), Karolinska Development (Vice President Business Development\/Portfolio Management). Otto har ocks\u00e5 en bred erfarenhet fr\u00e5n styrelsearbete fr\u00e5n start-up f\u00f6retag inom l\u00e4kemedelsbranschen.<\/p>\n<p>Anders Johansson har en doktorsexamen i materialkemi fr\u00e5n Uppsala universitet och \u00e4r medgrundare till Nanexa. Han har tidigare erfarenhet av arbete som patentkonsult p\u00e5 patentbyr\u00e5n Bjerk\u00e9ns KB. \u00a0Anders ers\u00e4tter M\u00e5rten Rooth, en annan av Nanexas grundare, d\u00e5 det finns en \u00f6verenskommelse om att de v\u00e4xelvis ska vara del av styrelsen.<\/p>\n<p>Nuvarande styrelseledam\u00f6terna Jan Sandstr\u00f6m och Christian \u00d6stberg har avb\u00f6jt omval.<\/p>\n<p>Styrelsearvodet f\u00f6resl\u00e5s uppg\u00e5 of\u00f6r\u00e4ndrat till 180\u00a0000 kronor till ordf\u00f6randen och till 90\u00a0000 kronor till \u00f6vriga av st\u00e4mman utsedda ledam\u00f6ter som inte \u00e4r anst\u00e4llda i bolaget. Vidare f\u00f6resl\u00e5s att arvode till revisorn ska utg\u00e5 enligt godk\u00e4nd r\u00e4kning.<\/p>\n<p>Till revisor f\u00f6resl\u00e5s \u00d6hrlings PricewaterhouseCoopers AB, som meddelat att de kommer att utse Lars Kylberg till huvudansvarig revisor. Lars Kylberg \u00e4r redan i dag bolagets revisor.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>F\u00f6r mer information kontakta:<\/p>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)<\/p>\n<p>Telefon: 0709-42 83 03<\/p>\n<p>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\">david.westberg@nanexa.se<\/a><\/p>\n<p>www.nanexa.com<\/p>\n<p>&nbsp;<\/p>\n<p>Om Nanexa AB (publ)<\/p>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell<sup>\u00ae<\/sup>som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell<sup>\u00ae<\/sup>har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pressmeddelande<\/p>\n<p>Uppsala 2019-06-04<\/p>\n<p>\u00a0<\/p>\n<p>Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019<\/p>\n<p>En grupp aktie\u00e4gare i Nanexa AB,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-1678","post","type-post","status-publish","format-standard","hentry","category-pressmeddelanden"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Pressmeddelande Uppsala 2019-06-04 \u00a0 Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 En grupp aktie\u00e4gare i Nanexa AB,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-04T07:54:10+00:00\" \/>\n<meta name=\"author\" content=\"Anders Johansson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skriven av\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders Johansson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/\"},\"author\":{\"name\":\"Anders Johansson\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\"},\"headline\":\"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019\",\"datePublished\":\"2019-06-04T07:54:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"articleSection\":[\"Pressmeddelanden\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/\",\"name\":\"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-06-04T07:54:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\",\"name\":\"Anders Johansson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"caption\":\"Anders Johansson\"},\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/author\\\/anders\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/","og_locale":"sv_SE","og_type":"article","og_title":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB","og_description":"Pressmeddelande Uppsala 2019-06-04 \u00a0 Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 En grupp aktie\u00e4gare i Nanexa AB,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/","og_site_name":"Nanexa AB","article_published_time":"2019-06-04T07:54:10+00:00","author":"Anders Johansson","twitter_card":"summary_large_image","twitter_misc":{"Skriven av":"Anders Johansson","Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/#article","isPartOf":{"@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/"},"author":{"name":"Anders Johansson","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a"},"headline":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019","datePublished":"2019-06-04T07:54:10+00:00","mainEntityOfPage":{"@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/"},"wordCount":479,"publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"articleSection":["Pressmeddelanden"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/","url":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/","name":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-06-04T07:54:10+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/beslutsforslag-infor-arsstamman-i-nanexa-ab-publ-den-11-juni-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Beslutsf\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman i Nanexa AB (publ) den 11 juni 2019"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a","name":"Anders Johansson","image":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","caption":"Anders Johansson"},"url":"https:\/\/nanexa.com\/sv\/author\/anders\/"}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=1678"}],"version-history":[{"count":1,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1678\/revisions"}],"predecessor-version":[{"id":1679,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1678\/revisions\/1679"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=1678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/categories?post=1678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/tags?post=1678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}